A Method to Direct the Differentiation of Human Induced Pluripotent Stem Cells into Ameloblasts and Odontoblasts

These present technologies offer a foundation for the development of periodontal regenerative therapies and further study of periodontal diseases affecting enamel and dentin formation.

Antibody-Based Inhibition of Uropathogenic E. coli Adhesion

The technology offers innovative antibody compositions that target the FimH adhesin of uropathogenic E. coli, preventing bacterial adhesion and biofilm formation.

Bikunin Biomimetic with Anti-Inflammatory and Antiviral Activity

The solution is a serine protease inhibitor, bikunin, that plays a role in controlling the early immune response to Influenza A virus.

Cell Barcoding for Multiplexed Pooled Screening of Perturbations in Cells

The solution is a novel pooled screening approach, called CellCode, that utilizes lentiviral barcoded libraries to encode perturbation histories in cells that are then decoded in downstream assays.

Computationally Designed Inhibitor for Epstein-Barr Virus BHRF1 Protein

The technology is a novel polypeptide designed to inhibit the Epstein-Barr virus BHRF1 protein, inducing apoptosis in infected cells and offering a potential therapeutic approach for Epstein-Barr-related diseases and cancers.

Constitutively Active cGAS for Enhanced Immune Response

This technology involves the design of constitutively active cyclic GMP-AMP synthase (cGAS) mutants that stimulate a robust immune response without the need for DNA binding.

Constitutively Active RIP Kinases/Caspases

The disclosed technology offers recombinant programmed cell death enzymes that can constitutively trigger apoptosis, pyroptosis or necroptosis. These novel proteins have the potential to cause rapid cell death in diseased cells and are available for immediate generation of IND-enabling data.

Custom Transmembrane β-Barrel Proteins

This technology involves the design of eight-stranded transmembrane β-barrel proteins (TMBs) with no homology to known TMBs, offering potential for a wide range of synthetic biology applications.

De Novo Designed Protein Binders Targeting TGFβRII, CTLA4, and PD-L1

Novel protein minibinders which bind to convex protein target sites on TGFβRII, CTLA4, and PD-L1 with high affinity and potent biological activity are the solution.

Deep Learning Approaches for Protein Scaffolding

This technology uses advanced deep learning methods to design proteins with specific functional sites, offering a novel approach to protein design that is both efficient and versatile.

Enhanced Influenza Hemagglutinin Binders

This technology offers innovative polypeptides that bind with high affinity to influenza hemagglutinin, offering potential applications in treatment, diagnosis, and prevention of influenza.

Glycosylated Nanoparticles for Vaccines

The solution is a method to engineer glycoproteins onto the surface of protein nanoparticle vaccine scaffolds to enhance vaccine-elicited immune responses.

High-Throughput Drug Screens on a 3D Tumor-on-a-Chip to Monitor Cancer Cell Viability and Migration

The solution is a three-dimensional human renal cell carcinoma (RCC)-on-a-chip for screening drugs that could be developed as anti-metastasis agents.

Homo-Oligomeric Protein Assemblies

The solution is a novel approach to design polypeptides that form cyclic homo-oligomers, offering potential applications in various fields.

IgG3 Spike Protein Binding Assay

The innovation offers a fast, inexpensive single-tier assay that offers clinical utility as a screening method to identify patients who have SARS-CoV-2 immunity based on the presence of spike-binding, neutralizing IgG3 antibodies against SARS-CoV-2

Increasing In Vivo Success of Stem Cells with GSK3 Inhibition

The disclosed innovation provides methods for increasing populations of hematopoietic, mesenchymal, mesodermal, or neural progenitor/ stem cells in vivo in a mammalian subject.

Injectable Recombinant Protein-Based Hydrogels for Therapeutic Delivery

The solution is a self-healing protein-based hydrogel that supports minimally invasive cell delivery through catheter injection.

Metabolite Biomarkers for the Detection of Colorectal Cancer

The technologies offer a simple yet powerful method for identifying serum markers of disease in colon cancer from peripheral blood. These technologies offer high sensitivity and specificity as compared to standard diagnostic methods such as colonoscopy but offer additional utility as they require no in-office clinical procedure. Together, they offer a promising new diagnostic and monitoring tool to support clinical decision making in colon cancer.

Method for Quantification of Lipoprotein(a)

The innovation offers a reference method for the quantification of lipoprotein(a) in clinical and research applications and serves to broaden the use of Lp(a) as a biomarker in cardiovascular disease outcome measurement and risk assessment.

Minibinder-Drug Conjugates Targeting Human EpCAM and PDL1 Receptors for Targeted Cancer Therapy

This technology offers a set of novel polypeptides designed to bind to human EpCAM and PDL1 receptors, offering potential applications in treating cancer, autoimmune diseases, and inflammation.

Mixed Chirality Peptide Macrocycles with Internal Symmetry

This technology leverages computational design to create mixed chirality peptide macrocycles with internal symmetry, offering a new avenue for therapeutic and nanomaterial design.

Modulating Prime Editing Efficiency Through Epigenetic Reprogramming

The innovation is a method that involves reprogramming the epigenetic environment in the vicinity of a target site to modulate prime editing efficiency.

Nanoactuators Based FePd Nanohelices to Initiate Cell Apoptosis

This technology offers a nan-actuator to initiate apoptosis and the removal of cancer cells. The nano-actuators magnetically is propelled to target cells and oscillate for mechanical damage of the cells.

Novel Nanoparticle Immunogens for Influenza Vaccines

This technology offers a new approach to influenza vaccines using computationally designed nanoparticle immunogens that elicit potent, neutralizing antibodies against influenza viruses.

Omega Muricholic Acid: A Novel PXR Ligand to Treat Hepato-Intestinal Diseases

The innovation offers a novel, murine-specific bile acid known as omega muricholic acid (wMCA). The technology has shown to be a promicing new avenue for the clinical management of inflammatory bowel disease (IBD).

Protein Homodimers with Tunable Symmetric Pockets: A Novel Approach to Binding Symmetric Molecules

This technology offers de novo designed protein homodimers with tunable symmetric pockets, enabling the binding of symmetric molecules for diverse applications.

Repurposing Combinations of Approved Drugs for Viral Outbreak Response and Readiness

The collection of technologies offers a simple yet powerful method for identifying combinations of previously FDA approved drugs with synergistic activity against viral infections. The technology is available for immediate use in preparation IND-enabling studies in high impact viral disease areas.

Secretion-Optimized Protein Nanoparticles for Eukaryotic Expression and Genetic Delivery

This technology offers innovative protein nanoparticles designed for efficient secretion in eukaryotic cells, enhancing genetic delivery and therapeutic applications.

Small Molecule Inhibitors for the Treatment of Epilepsy

The solution is a potential new therapeutic target related to inhibition of specific regulators of the WNT pathway that can prevent and/or treat epilepsy.

Systems and Methods for Deep Brain Stimulation Using Kinematic Feedback for Treatment of Movement Disorders

This technology offers the statistical analysis of gait parameters, a motor symptom of Parkinson’s disease. This system conducts deep brain stimulation and adapts its response with the stimulation frequency varying between low (i.e. 60 Hz) and high (>130 Hz) frequencies to improve gait.

Targeted Protein Degradation in Bacteria Contributes to Antibiotic Efficacy

The solution is a method to develop new antibiotic proteolysis targeting chimeras (PROTACs) that target proteins of interest for degradation in bacteria to counteract antibiotic resistance.

Targeting von Willebrand Factor to Model Disease in Human Pluripotent Stem Cells

The disclosed technology offers a CRISPR-Cas9 generated, isogenic hPSC-EC in-vitro model for studying disease dynamics and therapeutic candidates for VWF-deficient diseases such as Von Willebrand disease (VWD).

TERIS

Transmembrane Protein Pores

This technology offers the computational design of protein pores that can selectively conduct ions and enable the passage of small-molecule fluorophores, offering a new approach to creating transmembrane channels with potential applications in biotechnology and medicine.

Treating Mitochondrial Dysfunction in Heart Failure

This technology targets the root cause of heart failure by employing nicotinamide riboside (NR) to protect mitochondrial function and reduce inflammation, and normalizing MRPP2 levels to improve mitochondrial DNA processing, offering a potential avenue to reverse the course of heart failure.

Treponema Pallidum-Specific Aptamers for Syphilis Diagnostics

The solution is the development of Treponema pallidum-specific aptamers to be used in accurate point-of-care diagnostic assays for syphilis.

Utilizing Variant Transcripts of PSEN2 for Diagnosis and Treatment of Tauopathies

The solution is an alternatively spliced exon in PSEN2 that leads to an aberrant protein product, providing a potential target for therapeutic intervention for sporadic Alzheimer’s Disease.